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Introduction
Cancer of mammary gland represents the most fre-
quently developing female malignant tumour in
Europe and North America. In 2006 almost 300,000
new cases of the tumour were noted in the United
States and it resulted in around 41,000 deaths [1].
In Poland, more than 13,000 new cases of the
tumour were detected in 2005 and over 5,000 women
died of the cancer [2]. In turn, in Lower Silesia the
Lower Silesia Tumour Register in 2005 documented
1,117 new cases, which accounted for 21.9 % of all
new cases of malignant tumours noted in this region
of Poland [3]. As evident from the above data, the
problem of breast cancer is extremely significant for
health of the population and for financial resources
devoted to combat the disease. This seems even more
important when the still growing trend in the inci-
dence and the associated mortality are taken into
account [1-3].
The related risk factors, which affect incidence of
breast cancer, are known to include duration of expo-
sure to sex hormones and to estrogens in particular [4].
The elevated risk of the tumour is observed in women
with early menarche (before 12th year of age) and in
women with late menopause (after 55th year of age)
[4,5]. Also tamoxifen, the non-steroid drug which
blocks estrogen receptors, applied in women with
increased risk of developing breast cancer was found
to decrease probability of developing the disease by,
approximately 50% [6].
Considering the above, the routine evaluation of
estrogen receptors (ER) and progesterone receptors
(PgR) in all diagnosed cases of breast cancer seems
natural.
Ovarian granulosa cells represent the main source
of natural estrogens (17-β-estradiol, estron, estriol) in
the body. Aside from various functions, the hormones
stimulate development of mammary gland, both by
activation of growth in ductal epithelium and glandu-
lar alveoli and by development of adipose tissue and of
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connective tissue sublayer [5,6]. Estrogens and prog-
esterone exert a mitogenic effect on the cells which,
after a protracted period, may promote development of
tumours in mammary gland. Estrogens act by activa-
tion of specific receptors (ER), localized mainly in cell
nucleus, which play role of transcription factors [6-8].
In supplementary treatment of breast cancer also the
earlier mentioned tamoxifen is employed. It represents
a modifier of ER receptors, which inhibits, i.a., mitot-
ic activity of estrogens in cells of breast cancer [6,9].
Two types of ER are distinguished, including ER α
and ER β, which represent two distinct proteins, coded
by two separate genes [6,7]. Similarly PgR is mani-
fested in two isoforms, PgR-A and PgR-B. The two
latter proteins are coded by the same genes [10-14].
Expression of PgR depends on presence and normal
function of ER, since estrogen binding to its receptor
induces synthesis of PgR [10]. Presence of PgR is
accepted to provide index of undisturbed function of
ER and evaluation of PgR expression provides an indi-
rect index of estrogen response mechanisms [15]. The
dependence of PgR synthesis on normal function of
ER is confirmed by the fact that around 50 % of breast
cancers manifest expression of both ER and PgR while
expression of PgR alone can be noted in only 1-12%
breast cancers [16].
The variable which affect most the results of tamox-
ifen treatment involves levels of ER and PgR expression
in cells of breast cancer. According to EORTC criteria,
receptor positive cancers include the tumours in which,
using immunocytochemical technique, ER expression is
manifested by at least 10% cells [16]. Expression of ER
and PgR is noted in, approximately 60 % patients with
breast cancer while a single receptor only is expressed
in around 20% patients [6].
In treatment of breast cancer, tamoxifen can be used
only after a precise determination of ER and PgR
expression. In tumours of more than 20 mm in diameter,
determination of ER expression in a single random
biopsy may lead to erroneous evaluation. This reflects,
i.a., frequent heterogeneity of texture in breast tumours.
This study aimed at examination of correlation
between ER and PgR immunohistochemical expres-
sion in ductal breast cancer of >20 mm in diameter, in
which biopsies of the tumour were sampled from three
distinct locations. 
Materials and methods
Tissue samples. The material included ductal breast cancers
(pT2N0) manifesting G2 grade of malignancy and diameter of over
20 mm, sampled from 40 women of 56 to 75 years in age, subject-
ed to surgery in the post-menopausal period in 2002-2003 in Lower
Silesia Centre of Oncology in Wroclaw (DCO).
Immunohistochemistry. Following surgical dissection of the
lesion the entire tumour with the surrounding tissues was trans-
ferred for intra-operative examination in Department of Patho-
morphology, DCO. In the course of the examination, three inde-
pendent samples were taken for immunohistochemical tests from
each tumour, including the lateral one from the side of the axil-
la (ER-1; PgR-1); the median one (ER-2; PgR-2) and the medi-
al one, from the side of the sternum (ER-3; PgR-3). From every
tumour a representative sample was also taken for the intra-
operative examination. All the samples were fixed in 5% solu-
tion of buffered formaldehyde and, then, embedded in paraffin
blocks. Formalin-fixed, paraffin-embedded tissue was cut 
(4 μm). The sections were mounted on Superfrost-Plus slides (Men-
zel Gläser, Germany), dewaxed with xylene and gradually rehydrat-
ed. Activity of endogenous peroxidase was blocked by 5 min expo-
sure to 3% H202. Detection of ER and PgR expression was preceded
by 15 min exposure of the sections in a microwave oven to boiling
Antigen Retrieval Solution (DakoCytomation, Denmark) at 250 W.
For demonstration of ER and PgR expression in the paraffin sec-
tions, were used mouse monoclonal antibodies: clone 1D5 and clone
PgR636 in the following concentrations: 1:50 and 1:100 (DakoCy-
tomation, Denmark). The antibodies were diluted in the Antibody
Diluent, Background Reducing (DakoCytomation, Denmark). The
sections were incubated with an antibody for 1h at room tempera-
ture. Subsequently, incubations were preformed with biotinylated
antibodies (15min, room temperature) with streptavidin-biotinylated
peroxidise complex (15min, room temperature) (LSAB2, HRP,
DakoCytomation, Denmark). DAB (DakoCytomation, Denmark)
was used as a chromogen (7 min, room temperature). All the sections
were counterstained with Meyer's hematoxylin. In every case, con-
trols were included in which specific antibody was substituted by the
Primary Negative Control (DakoCytomation, Denmark).
Light microscopy. Intensity of ER and PgR expression was stud-
ied using OLYMPUS BX-41 light microscope coupled to a vision
pathway and computer-assisted image analysis system, AnalySIS
3.2 (Olympus; Japan). In each evaluated section (examined at the
magnification of ×200) three hot spots were selected in which
expression of ER and PgR was most pronounced. Subsequently, at
the magnification of ×400, the computer-assisted image analysis in
the regions permitted to automatically score cancer cell nuclei with
positive reaction as related to all cell nuclei in the tumour. The
result represented percentage of positive cancer cell nuclei as relat-
ed to all tumour cell nuclei in evaluated regions.
Statistical analysis. The obtained results were subjected to statis-
tical analysis using Pearson's correlation and taking advantage of
STATISTICA 7.1 software. Values corresponding to the level of
p<0.05 were accepted as statistically significant.
Results
In 21 out of 40 examined cases of breast cancer
nuclear expression of both ER and PgR was detected
in all isolated samples (Fig. 1). Distribution of ER and
PgR expression intensity in individual regions of the
tumour is presented in Table 1. Using the results of
proportional expression of ER and PgR analysis of
Pearson's correlation was conducted in individual
regions of the tumours.
Comparing results related to ER-1 and ER-2
expression in the examined breast cancers their mod-
erately positive correlation was disclosed (r=0.43;
p<0.05) (Fig. 2A); ER-1 and ER-3 manifested 
a strongly positive correlation (r=0.62; p<0.05) 
(Fig. 2B) while ER-2 and ER-3 showed a weak posi-
tive correlation (r=0.28; p<0.05) (Fig. 2C). 
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Studies on relationships between PgR expressions
detected a weak positive correlation between expres-
sions of PgR-1 and PgR-2 (r= 0.25; p<0.05) (Fig. 3A);
a relatively strong positive correlation between PgR-1
and PgR-3 (r=0.49; p<0.05) (Fig. 3B) and a very weak
positive correlation between PgR-2 and PgR-3
(r=0.12; p<0.05) (Fig. 3C). In addition we conducted an
analysis of correlation between expression of ER with
that of PgR in the same regions of studied tumours and
we demonstrated a strong positive relationship between
ER-1 and PgR-1 expressions (r=0.64; p<0.05) (Fig. 4A)
and between ER-2 and PgR -2 expressions (r=0.60;
p<0.05) (Fig. 4B) while in the case of ER-3 and PgR-3
expression we observed a moderately positive relation-
ship (r=0.39; p<0.05) (Fig. 4C).
Discussion
Role of ER and PgR in biology of breast cancer has
been widely documented in literature of the subject.
Contents of the receptors in tumour cells represent 
a strong predictive factor, which plays a significant
role in prognosis and in selection of therapeutic deci-
sion, including start of hormonal therapy [17].
Almost 75% of primary breast cancers demonstrate
positive expression of ER and more than half of them
co-express PgR [6]. The higher is ER and PgR content
in breast cancer, the higher is probability of obtaining
response to hormonal therapy [18-20]. 
Evaluation of ER and PgR contents in breast cancer
cells used to take advantage of three principal tech-
niques, including the ligand binding test, immunoen-
zymatic test (EIA) and immunohistochemical tests
(IHC) [16].
Even if biochemical studies and immunohisto-
chemical tests yield consistent data and the obtained
results corroborate each other in 60% to almost 90%
cases [16,21-23], at present IHC represents the recom-
mended technique [24-26]. In comparison to EIA the
technique is more sensitive and more specific [24].
Moreover, it allows for analysis of neoplastic cells
only, excluding the stromal cells and the normal glan-
dular epithelium [24]. IHC yields positive results both
for ER and PgR, even if EIA test is negative, particu-
larly in poorly differentiated tumours [25]. IHC repre-
sents also the only option in cases of tumours of small
dimensions (of few mm in diameter) [24].
Results of our study unequivocally point to rela-
tively extensive variability in the level of receptor
expression between median zone of the tumours and
tumour margins. The relationship pertain both, ER and
PgR. Moreover,  a pronounced significant positive cor-
relation has been disclosed between expressions of the
two types of receptors in a given tumour zone. The
results may be explained by the variable levels of ER
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Fig. 1. Nuclear expression (brown nuclei) of estrogen receptors (ER)-(A) and progesterone receptors (PgR)-(B) in ductal breast cancers.
Immunohistochemical technique, counterstained with hematoxylin (original magnification x200).
Table 1. Distribution of ER and PgR expression intensity in indi-
vidual tumour zones.
and PgR expressions depending on proliferative activ-
ity of tumour cells, commented in the literature 
[27-29]. ER have been shown to manifest a relatively
short half-life and, therefore, they are most abundant in
mitotically active cells [27-29]. Comparing our results
related to distribution of ER and PgR expression inten-
sity with the data obtained by other authors it could be
suggested that our results reflect an enhanced mitotic
activity of breast cancer cells at margins of the tumour
[27-29]. Median zone of a tumour used to manifest
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Fig. 2. Correlation (p<0.05) of estrogen receptors (ER) and prog-
esterone receptors (PgR) expression as related to localization with-
in the tumour: 1 – margin on axillary side; 2 – median zone; 3 –
margin on sternal side. A: ER-1 vs ER-2; r=0.43. B: ER-1 vs ER-3;
r=0.62. C: ER-2 vs ER-3; r=0.28.
Fig. 3. Correlation (p<0.05) between expression of estrogen recep-
tors (ER) and of progesterone receptors (PgR) expression as relat-
ed to localization within the tumour: 1 – margin on axillary side; 
2 – median zone; 3 – margin on sternal side. A: PgR-1 vs PgR-2;
r=0.25. B: PgR-1 vs PgR-3; r=0.49. C: PgR-2 vs PgR-3; r=0.12.
lower proliferative activity and, therefore, lower
expression of ER [27-29]. The relation may also be
responsible for results of studies conducted by Jakesz
et al. [27] who demonstrated higher expression of
receptors in metastatic cells (in lymph node metas-
tases) of a higher proliferative activity as compared to
cells in the primary lesion.
Our observations have also been confirmed by the
study performed by Davis et al. [30]. The authors
analysed tumours of lower dimensions (diameter <20
mm), detecting differential levels of ER and PgR
expression depending on localization of the studied
material within the tumour mass. A markedly higher
ER and PgR expression was noted at the periphery of
small tumours as compared to their centre [30]. Thus,
it seems that distribution of ER and PgR expression
does not change with increase in tumour volume,
remaining most pronounced at margins of the tumour.
Considering clinico-therapeutic implications of ER
and PgR expression it seems necessary to perform
detailed IHC studies on margins of large tumours. In
such situations, in contrast to tumours of small dimen-
sions, a significantly higher risk exists for subjecting
to analysis of exclusively their central zone, which in
contrast to their peripheral zone may prove receptor-
negative or receptor poorly positive. This in turn may
result in an erroneous therapeutic decision: the patient
my be disqualified from hormonal therapy. This in turn
may negatively affect the prognosis. 
Conclusion
In our studies we have demonstrated a significant vari-
ability in ER and PgR expression, related to evaluated
zone of the tumour. This confirms the heterogenous
character of histological texture of ductal breast cancers
and it may carry diagnostic and therapeutic implications
in the context of administration of hormonal therapy.
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